Actualités

Vertex Pharmaceuticals agreed to acquire Crinetics Pharmaceuticals for about US$10b, reigniting takeover speculation across the obesity drug sector. Following this deal, Viking Therapeutics (NasdaqCM:VKTX) has drawn fresh attention as a possible M&A target. Investor focus is increasing on upcoming data for VK2735 and the recently initiated Phase 1 trial of VK3019. Viking Therapeutics sits at the intersection of obesity and metabolic drug development, an area that has attracted large capital...

This buy gives Vertex both a recently-commercialized drug, and a very strong lead candidate.

CRINETICS PHARM (CRNX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Wall Street sees bigger upside in VKTX, with Koyfin’s average target implying 120% upside versus 99% for BCRX.

Investors favored companies benefiting from biotech deals, rising power demand from AI data centers, and cost-cutting efforts to improve profits.

The drugmaker is paying up for a new growth engine. Is the price disciplined?

Crinetics stock nearly doubled after Vertex agreed to buy it for $10 billion. What's behind the deal, and is it worth it?

Vertex Pharmaceuticals (VRTX) closed at $522.25 in the latest trading session, marking a -1.39% move from the prior day.

Vertex Pharmaceuticals (NasdaqGS:VRTX) agreed to acquire Crinetics Pharmaceuticals for US$10b. The deal adds a marketed rare disease drug and moves Vertex into endocrinology as a new business area. The transaction is positioned to expand Vertex's portfolio beyond its existing core franchises. Vertex Pharmaceuticals has built its business around treatments for rare and serious diseases, and the planned Crinetics acquisition marks a shift into endocrinology with an FDA approved therapy and...

Healthcare stocks were higher late Tuesday afternoon, with the NYSE Healthcare Index and the State S

An all-cash deal at $85 per share adds an FDA-approved acromegaly pill

Shares of Vera Therapeutics rose about 8% Tuesday after the Food and Drug Administration approved its treatment for a kidney disease, IgA nephropathy, that affects about 160,000 people in the U.S. and often leads to kidney failure. The drug, called Trutakna, works by blocking two proteins that push the immune system to make antibodies that build up in the kidneys and cause damage. It is the first drug approved in the U.S. that targets both proteins at once, though several other drugs already treat the disease.

Vertex Pharmaceuticals (VRTX) and Crinetics Pharmaceuticals (CRNX) said late Monday they have reache

On CNBC’s Mad Dash segment on Monday, July 6, 2026, Jim Cramer made one of his most bullish biotech calls in years, arguing that the sector could be entering a new wave of mergers and acquisitions as the regulatory environment becomes more favorable for dealmaking. “There is a move in biotech that we have not ... Jim Cramer Calls Biotech “The Hottest Group in the Market” as He Predicts “Deals Are Going to Be Flooding the Market”

All three major US stock indexes were down in late-morning trading Tuesday, with the Nasdaq Composit

One has FDA approval and revenue; the other is pre-commercial but debt-free. Both face distinct risks that could reshape your biotech bet.

H.C. Wainwright said Crinetics’ lead product Palsonify adds a meaningful commercial product and establishes endocrinology as Vertex’s fifth major business pillar.

Vertex to acquire CRNX for $10B, adding approved rare disease drug Palsonify and late-stage pipeline assets to expand its endocrinology portfolio.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) on Monday agreed to acquire Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) for $85 per share in cash, a total equity value of approximately $10 billion ($8.8 billion net of cash). Vertex expects to finance the acquisition using a combination of cash on hand and debt, supported by $4.5 billion of fully committed bridge financing. Vertex’s cash, cash equivalents, and total marketable securities as of March 31, 2026, were $13.0 billion. Read Also: Ver

The deal gives Vertex access to Palsonify, an oral acromegaly treatment, and atumelnant, a late-stage drug for congenital adrenal hyperplasia

US equity futures were mostly pointing lower before the open Tuesday amid a broad sell-off in chip s

AI stocks take a beating, with South Korean memory-chip maker Samsung Electronics setting the tone for the broader market.

(Bloomberg) -- US stock futures pointed to renewed weakness in technology shares after Samsung Electronics Co.’s earnings failed to satisfy investors, renewing pressure on chipmakers across global markets.Most Read from BloombergGreece Offers Bounty to Catch Ravenous Fish Lured by Warming SeaMicrosoft’s Xbox to Cut 3,200 Jobs, Divest Five Studios in Major OverhaulTwo Millennium Trading Pods Made About $3.7 Billion Last MonthSaudis Slash Main Oil Price to Rare Discount as Market DivesChina Senten

Crinetics Pharmaceuticals stock was surging on Tuesday after Vertex Pharmaceuticals said it had agreed to buy the biotech for $10 billion. Vertex slid 1.2%. Vertex said in a press release late Monday that it would buy Crinetics, which specializes in discovering and developing treatments for endocrine diseases, for $85 a share in cash.

Vertex Pharmaceuticals (VRTX) agreed to acquire endocrine disease drugmaker Crinetics Pharmaceutical

The acquisition is expected to close in the third quarter of 2026.

AI stocks take a beating, with South Korean memory-chip maker Samsung Electronics setting the tone for the broader market.

Crinetics Pharmaceuticals stock has delivered a strong 112.8% return over the past three years, yet its valuation checks paint a mixed picture at the same time as investors weigh the agreed US$85 per share cash acquisition by Vertex Pharmaceuticals against the current market pricing. Over the last three years, Crinetics Pharmaceuticals has returned 112.8%, which puts recent gains in the context of a longer period of substantial shareholder returns. Vertex's planned US$10b cash acquisition,...

Vertex claimed the two drugs in the deal could eventually bring in more than $5 billion annually. Still, the high price it paid stirred debate among analysts and investors.

In a world where many businesses have shaky balance sheets, some have ignored the crowd and exercised prudence. These cash-heavy companies shine bright for their financial discipline, resilience, and ability to generate solid returns.